Results of the Annual General Meeting

Tampere, Finland and Guildford, UK. 25 April 2007...Inion Oy (LSE: IIN) announces that all resolutions proposed to shareholders at its Annual General Meeting held yesterday were duly passed.

The following resolutions were passed at the AGM:

(I) Matters belonging to the Annual General Meeting in accordance with 12 § of the Articles of Association

1. That the annual accounts for the year ended 31 December 2007 be adopted;

2. That no dividend be declared in respect of the year 2007;

3. That the Directors and the Chief Executive Officer be discharged from liability;

4. Number of Directors to be decreased to seven (7);

5 – 11. Re-election of each of the following as Director: Göran Ando, David Anderson, Jim Beery, Julien Cotta, Peter Jensen, Chris Lee, Markku Silén

12. Resolve on the remuneration to the auditors, PricewaterhouseCoopers Oy.

(II) Proposals by the Board for authority to the Board of Directors to issue

Shares

13. Authorisations for the Board of Directors to issue shares as follows:

i Authorisation for the Board of Directors to issue no more than 7,343,000 shares to strengthen the Company’s capital structure

ii Authorisation for the Board of Directors to issue no more than 800,000 shares in respect of the remuneration of Non-Executive Directors; and

iii Authorisation for the Board of Directors to issue no more than 2,240,000 shares in respect of the 2008 equity-based incentive scheme.

The maximum number of shares to be issued under these authorisations will thus not exceed 10,383,000 shares.

-ends-

For further information, please contact:

Inion Oy
Göran Ando, Chairman

Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer

Tel: +44 (0)1483 685390

Citigate Dewe Rogerson
Mark Swallow / David Dible

Tel: +44 (0)207 638 9571

About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima™ family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.

08_INI_06 AGM.pdf (26.2 kilobytes)

Previous | Next